DEA, HHS Extend Telemedicine Flexibilities for Controlled Substance Prescriptions Through 2025

Lexology November 26, 2024
Holland & Knight LLP

Highlights

• Pursuant to new regulations issued by the U.S. Drug Enforcement Administration (DEA) and U.S. Department of Health and Human Services (HHS) (collectively, the Agencies) on Nov. 11, 2024, providers will be able to continue prescribing Schedule II-V controlled medications via telemedicine without an in-person evaluation until Dec. 31, 2025.
• This is the third extension of the telemedicine flexibilities and is intended to maintain the status quo while the Agencies develop a longer-term solution.
• The flexibilities are subject to the same requirements as previous extensions.

The U.S. Drug Enforcement Agency Administration (DEA) and U.S. Department of Health and Human Services (HHS) (collectively, the Agencies) on Nov. 11, 2024, issued a third extension of their telemedicine flexibilities for the...

Today's Sponsors

Today's Sponsor